Unfolding narratives, shaping futures

We're always working to initiate change for patients

This section includes information and helpful resources so you can stay up to date on the latest UroGen innovations, events, news coverage, and more.

UroGen® profile

UroGen is a biotech company dedicated to developing and commercializing innovative solutions that treat urological and specialty cancers because patients deserve better options. UroGen has developed a proprietary innovative technology platform, RTGel®, a reverse-thermal sustained-release hydrogel that has the potential to improve therapeutic profiles of existing drugs. UroGen’s sustained-release technology is designed to work with the urologic anatomy—not against it—enabling longer exposure of the urinary tract tissue to medications and making local therapy a potentially more effective treatment option.

Jelmyto® (mitomycin) for pyelocalyceal solution and investigational treatment UGN-102 (mitomycin) for intravesical solution for patients with low-grade intermediate risk non-muscle invasive bladder cancer, are designed to ablate tumors by nonsurgical means. UroGen is headquartered in Princeton, NJ with operations in Israel.

See our pipeline

Our leadership

See full leadership team

News releases

May 12, 2025

UroGen Pharma Reports First Quarter 2025 Financial Results and Provides a Business Update

New Drug Application for UGN-102 on track for FDA-PDUFA target action date of June 13, 2025 ; assuming approval, commercial launch to immediately follow with product availability in July Oncologic Drugs Advisory Committee scheduled for May 21, 2025 JELMYTO ® achieved net product sales of $20.3

Read story

May 7, 2025

UroGen Announces FDA Advisory Committee for UGN-102, an Investigational Treatment for Recurrent Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer

PRINCETON, N.J. --(BUSINESS WIRE)--May 7, 2025-- UroGen (NASDAQ: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced that the U.S. Food and Drug Administration (FDA) has scheduled an Oncologic Drugs

Read story

May 1, 2025

UroGen Pharma to Report First Quarter 2025 Financial Results on Monday, May 12, 2025

Conference Call and Webcast Scheduled for Monday, May 12, 2025 , at 10:00 AM ET PRINCETON, N.J. --(BUSINESS WIRE)--May 1, 2025-- UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today

Read story

Events

May 12, 2025

UroGen Pharma Q1 2025 Earnings Call

Listen to webcast

Mar 10, 2025

UroGen Pharma Q4 2024 Earnings Call

Listen to webcast

Mar 3, 2025

TD Cowen 45th Annual Health Care Conference

Listen to webcast

Feb 20, 2025

Advancing Our Mission to Transform Cancer Care

Listen to webcast

Feb 11, 2025

Oppenheimer 35th Annual Healthcare Life Sciences Conference

Listen to webcast

Feb 5, 2025

Guggenheim Securities SMID Cap Biotech Conference

Listen to webcast

Nov 6, 2024

UroGen Pharma Q3 2024 Earnings Call

Listen to webcast

Sep 17, 2024

2024 Cantor Global Healthcare Conference

Listen to webcast

Sep 9, 2024

H.C. Wainwright 26th Annual Global Investment Conference

Listen to webcast

Aug 13, 2024

UroGen Pharma Q2 2024 Earnings Call

Listen to webcast
Connect with us
For more information about our products